Please note that we have stopped the regular imports of Gene Expression Omnibus (GEO) data into ArrayExpress. This may not be the latest version of this experiment.

E-GEOD-22368 - Primary human erythroid progenitor cells NK57 treatment samples

Status
Released on 29 July 2010, last updated on 1 May 2014
Organism
Homo sapiens
Samples (9)
Array (1)
Protocols (8)
Description
Gene expression profiling was performed on primary human erythroid progenitor cells left untreated or treated with 2uM NK57 for 3 days. The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born with the disease each year in Africa alone. Induction of fetal hemoglobin is a validated strategy to improve symptoms and complications of this disease. The development of targeted therapies has been limited by the absence of discrete druggable targets. We developed a novel bead-based strategy for the identification of inducers of fetal hemoglobin transcripts in primary human erythroid cells. A small-molecule screen of bioactive compounds identified remarkable class-associated activity among histone deacetylase (HDAC) inhibitors. Using a chemical genetic strategy combining focused libraries of biased chemical probes and reverse genetics by RNA interference, we have identified HDAC1 and HDAC2 as molecular targets mediating fetal hemoglobin induction. Our findings suggest the potential of isoform-selective inhibitors of HDAC1 and HDAC2 for the treatment of sickle cell disease. Gene expression profiling was performed on primary human erythroid progenitor cells left untreated (n=7) or treated with 2uM NK57 for 3 days (n=2).
Experiment type
transcription profiling by array 
Contacts
Benjamin L Ebert, James E Bradner, Kenneth N Ross
MIAME
PlatformsProtocolsVariablesProcessedRaw
Files
Investigation descriptionE-GEOD-22368.idf.txt
Sample and data relationshipE-GEOD-22368.sdrf.txt
Raw data (1)E-GEOD-22368.raw.1.zip
Processed data (1)E-GEOD-22368.processed.1.zip
Array designA-AFFY-33.adf.txt
R ExpressionSetE-GEOD-22368.eSet.r
Links